GleamWall
中文EN

CPHI CHINA PHARMA HOLDINGS, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1106644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.4%
TTM net income YoY-79.5%
TTM EPS YoY71.8%
Revenue 3-yr CAGR-17.9%
Net income 3-yr CAGR—

Margins

Gross margin14.2%
Operating margin-130.5%
Net margin-132.8%
FCF margin—
EBITDA margin-89.0%

Returns

ROE-24.2%
ROA-18.3%
ROIC (approx.)-20.5%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets16.8%
Debt / equity0.00x
Current ratio0.77x
Interest coverage-157.66x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.15M$948,340$983,536$1.23M$756,217$1.03M$1.14M$1.13M
Cost of revenue$1.06M$864,774$698,049$1.08M$815,871$1.11M$1.27M$1.29M
Gross profit$91,974$83,566$285,487$150,775-$59,654-$87,010-$136,061-$160,589
R&D expense$16,369$19,135$83,762$190,041$40,321$20,952$29,587$547
SG&A expense$1.31M$1.38M$1.23M$1.08M$424,827$440,834$507,182$859,373
Operating income-$1.88M-$1.43M-$1.12M-$1.20M-$628,145-$652,120-$758,618-$1.20M
Interest expense$10,414$9,306$9,085$6,879$6,798$6,771$6,787$6,802
Pretax income-$1.90M-$1.46M-$1.14M-$1.22M-$651,482-$528,367-$785,572-$1.22M
Net income-$1.90M-$1.46M-$1.14M-$1.22M-$651,482-$528,367-$785,572-$1.22M
EBITDA-$1.71M-$1.28M-$136,694-$702,770-$470,069-$488,617-$429,305-$747,963
EPS (basic)-0.04-0.04-0.04—-0.17-0.16-0.24—
EPS (diluted)-0.04-0.04-0.04—-0.17-0.16-0.24—
Weighted avg. shares (diluted)42.42M40.52M25.60M—3.87M3.23M3.26M—
Balance sheet
Cash & equivalents$3.68M$304,874$168,474$345,112$267,625$625,032$412,688$626,879
Receivables$196,588$181,621$196,262$241,412$224,638$268,793$328,901$232,140
Inventory$1.32M$1.36M$1.50M$1.62M$1.65M$1.68M$1.98M$2.27M
Current assets$5.39M$2.01M$2.00M$2.35M$2.33M$2.70M$2.85M$3.27M
PP&E, net$4.12M$4.22M$4.30M$4.39M$4.50M$4.63M$4.78M$4.88M
Intangibles$37.30M$38.34M$38.67M$24.08M$8.78M$6.44M$6.57M$6.70M
Total assets$46.93M$44.71M$45.14M$31.00M$15.80M$13.77M$14.22M$14.89M
Current liabilities$7.03M$7.68M$7.27M$7.40M$6.62M$5.25M$5.12M$5.02M
Short-term debt$1.57M$1.64M$1.47M$1.44M$1.41M$1.41M$1.15M$1.14M
Total liabilities$7.86M$8.53M$8.12M$8.26M$7.49M$7.30M$7.25M$7.14M
Shareholders' equity$39.07M$36.18M$37.02M$22.74M$8.31M$6.46M$6.97M$7.75M
Shares outstanding43.02M40.52M40.52M5.52M3.26M3.26M3.26M3.26M
Cash flow statement
Operating cash flow-$1.11M-$32,828-$55,292$151,990-$236,987$274,307-$73,676$238,474
Capital expenditure———$454$611-$65$58,324$19,545
Free cash flow———$151,536-$237,598$274,372-$132,000$218,929
Investing cash flow———-$5,767-$40,598$65-$58,324-$272,852
Financing cash flow$4.50M$120,118-$79,325-$72,592-$122,214-$29,188-$76,820$6,802
Depreciation & amortization$163,063$150,327$980,570$497,425$158,076$163,503$329,313$448,073
Stock-based compensation—$0$0——$0——

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.